ASKC202 + limertinib

**ASKC202 + limertinib** is a combination therapy comprised of two oral small molecule drugs: - **ASKC202** is a highly selective c-Met (hepatocyte growth factor receptor) inhibitor developed by Jiangsu Aosaikang Pharmaceutical. c-Met is implicated in tumor cell growth, survival, invasion, and metastasis, making it a key target in cancer therapy[1][3][6]. - **Limertinib** is a third-generation EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor (TKI), developed by Innovent and ASK Pharm, indicated for EGFR-mutant non-small cell lung cancer (NSCLC)[2][4]. This combination is being investigated, especially for patients with NSCLC who have MET amplification/overexpression and failed prior EGFR-TKI therapy. The mechanism leverages dual inhibition of the c-Met and EGFR pathways to overcome resistance mechanisms observed in advanced NSCLC.

Other names

ASKC202ASKC-202ASKC 202limertinib